Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491010 | 0.84 | AAK1 (0.34) | AAK1 | |
| SCHEMBL1490941 | 0.78 | AAK1 (0.40) | METAAK1SMN1; SMN2MAPTGSTP1 | |
| SCHEMBL1490785 | 0.76 | ALDH1A1 (0.37) | CYP2C19CYP1A2SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL1490847 | 0.76 | ALDH1A1 (0.36) | CYP2C19CYP1A2SMN1; SMN2MAPT | |
| SCHEMBL1490885 | 0.73 | LMNA (0.33) | CYP2C19GAALMNACYP1A2SMN1; SMN2 | |
| SCHEMBL26310184 | 0.71 | AAK1 (0.37) | METAAK1CYP2C19GAALMNA | |
| SCHEMBL1490888 | 0.70 | MAPT (0.33) | METCYP2C19GAALMNACYP1A2 | |
| SCHEMBL5799069 | 0.70 | PTGES (0.38) | METAAK1GAALMNASMN1; SMN2 | |
| SCHEMBL5415676 | 0.70 | NPC1 (0.46) | METAAK1GAASMN1; SMN2MAPT | |
| SCHEMBL3162668 | 0.69 | GSTM2 (0.38) | GAALMNASMN1; SMN2MAPTGSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| WO-2006038923-A2 | ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | MET 930/4885AAK1 2808/4885CYP2C19 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.